Helping donors and funders carry out vaccine development programs

VFI supports the vision of a healthier world with tried and trusted expertise and network.

VFI is striving to open up access to relevant knowledge for the development of affordable and efficient adjuvanted vaccines. VFI’s funding by the Bill & Melinda Gates Foundation and the European Commission underline VFI’s not-for-profit engagement for the benefit of developing countries.

Current funders

Bill & Melinda Gates Foundation (BMGF)

Reference:
Marcandalli, J. et al. Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus. Cell 176, 1420-1431.e17 (2019).

Coalition for Epidemic Preparedness Innovations (CEPI)
European Commission (EC) / Swiss State Secretariat for Education, Research and Innovation (SERI)

ISIDORe

“Integrated Services for Infectious Disease Outbreak Research” is an EU-funded large-scale project which assembles an unprecedented One Health-driven, integrated portfolio of cutting-edge research services and resources, dedicated to the study of epidemic-prone diseases including SARS-CoV-2 variants.

ISIDORe

VFI provides support on adjuvant development, non-GLP in vivo studies, technology transfer of adjuvants and provision of GMP adjuvant for use in clinical studies.
Visit website
National Institutes of Health (NIH)
Past
Bill & Melinda Gates Foundation (BMGF)

VAGH

VAGH (VFI Adjuvants for Global Health) aims at developing a broad portfolio of adjuvants for use in Global Health vaccines.

VAGH

Visit website
European Commission (EC)

TRANSVAC

TRANSVAC aims at developing a sustainable vaccine infrastructure for Europe.

TRANSVAC

VFI coordinates TRANSVAC activities and provides training as well as adjuvant and formulation services.
Visit website

Reference:
Geels, M. J. et al. TRANSVAC research infrastructure – Results and lessons learned from the European network of vaccine research and development. Vaccine 33, 5481–5487 (2015)

Reference:
Schijns, V. et al. Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. Immunol Rev 296, 169–190 (2020) and Lemoine, C. et al. Technological Approaches for Improving Vaccination Compliance and Coverage. Vaccines 8, 304 (2020)

Swiss National Science Foundation (SNSF)

Not-for-profit status

VFI is incorporated in The Republic and canton of Geneva, Switzerland, as a not-for-profit company. In light of its not-for-profit mission and activities VFI has been recognized of public utility and granted tax exemption ruling from the Tax Authorities of the Republic and Canton of Geneva. VFI is also certified equivalent to a U.S. public charity pursuant to U.S. IRC § 501(c)(3).

Contact us to let us help you reach your goals